PL1909843T3 - Przeciwnowotworowe biokoniugaty kwasu hialuronowego lub jego pochodne otrzymane przez pośrednie sprzęganie chemiczne i ich zastosowanie w dziedzinie farmacji - Google Patents

Przeciwnowotworowe biokoniugaty kwasu hialuronowego lub jego pochodne otrzymane przez pośrednie sprzęganie chemiczne i ich zastosowanie w dziedzinie farmacji

Info

Publication number
PL1909843T3
PL1909843T3 PL06762981T PL06762981T PL1909843T3 PL 1909843 T3 PL1909843 T3 PL 1909843T3 PL 06762981 T PL06762981 T PL 06762981T PL 06762981 T PL06762981 T PL 06762981T PL 1909843 T3 PL1909843 T3 PL 1909843T3
Authority
PL
Poland
Prior art keywords
bioconjugates
anticancer
hyaluronic acid
pharmaceutical field
chemical coupling
Prior art date
Application number
PL06762981T
Other languages
English (en)
Inventor
Davide Renier
Fabio Bettella
Original Assignee
Fidia Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fidia Farmaceutici S.P.A. filed Critical Fidia Farmaceutici S.P.A.
Publication of PL1909843T3 publication Critical patent/PL1909843T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL06762981T 2005-08-03 2006-08-02 Przeciwnowotworowe biokoniugaty kwasu hialuronowego lub jego pochodne otrzymane przez pośrednie sprzęganie chemiczne i ich zastosowanie w dziedzinie farmacji PL1909843T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000242A ITPD20050242A1 (it) 2005-08-03 2005-08-03 Bioconiugati antitumorali dell'acido ialuronico o dei suoi derivati, ottenibili per coniugazione chimica diretta o indiretta, e loro impiego in campo farmaceutico

Publications (1)

Publication Number Publication Date
PL1909843T3 true PL1909843T3 (pl) 2017-03-31

Family

ID=37038336

Family Applications (3)

Application Number Title Priority Date Filing Date
PL06762981T PL1909843T3 (pl) 2005-08-03 2006-08-02 Przeciwnowotworowe biokoniugaty kwasu hialuronowego lub jego pochodne otrzymane przez pośrednie sprzęganie chemiczne i ich zastosowanie w dziedzinie farmacji
PL11159629T PL2537533T3 (pl) 2005-08-03 2006-08-02 Przeciwnowotworowe biokoniugaty kwasu hialuronowego lub jego pochodne otrzymane przez pośrednie sprzęganie chemiczne
PL11159649T PL2540319T3 (pl) 2005-08-03 2006-08-02 Przeciwnowotworowe biokoniugaty kwasu hialuronowego lub jego pochodne otrzymane przez pośrednie sprzęganie chemiczne

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL11159629T PL2537533T3 (pl) 2005-08-03 2006-08-02 Przeciwnowotworowe biokoniugaty kwasu hialuronowego lub jego pochodne otrzymane przez pośrednie sprzęganie chemiczne
PL11159649T PL2540319T3 (pl) 2005-08-03 2006-08-02 Przeciwnowotworowe biokoniugaty kwasu hialuronowego lub jego pochodne otrzymane przez pośrednie sprzęganie chemiczne

Country Status (18)

Country Link
US (1) US9687558B2 (pl)
EP (4) EP2548582B1 (pl)
JP (2) JP5457672B2 (pl)
KR (1) KR101614157B1 (pl)
CN (2) CN103041402A (pl)
AU (1) AU2006274992B2 (pl)
BR (1) BRPI0614536A2 (pl)
CA (1) CA2616957C (pl)
DK (2) DK2537533T3 (pl)
ES (4) ES2633291T3 (pl)
IL (1) IL189078A0 (pl)
IT (1) ITPD20050242A1 (pl)
NO (1) NO20080564L (pl)
NZ (1) NZ565504A (pl)
PL (3) PL1909843T3 (pl)
RU (1) RU2411958C2 (pl)
SI (3) SI1909843T1 (pl)
WO (1) WO2007014784A2 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1905456A4 (en) * 2005-07-06 2010-12-22 Seikagaku Kogyo Co Ltd PHARMACEUTICAL LIGHT-NETWORKED HYALURONIC DERIVATIVE GEL
ITMI20071267A1 (it) 2007-06-22 2008-12-23 Fidia Farmaceutici Uso di coniugati dell'acido ialuronico nel trattamento locale di malattie cutanee iperproliferative
IE20070900A1 (en) * 2007-12-12 2009-06-24 Eurand Pharmaceuticals Ltd New anticancer conjugates
US20120100218A1 (en) * 2008-01-30 2012-04-26 Laird Forrest Intralymphatic Chemotherapy Drug Carriers
WO2009097570A2 (en) * 2008-01-30 2009-08-06 University Of Kansas Intralymphatic chemotherapy drug carriers
US9789200B2 (en) 2008-04-22 2017-10-17 Fidia Farmaceutici S.P.A. Therapeutic use of new pharmaceutical preparations containing antitumoral drugs bound to hyaluronic acid in the treatment of neoplasias
IT1391006B1 (it) * 2008-10-08 2011-10-27 Fidia Farmaceutici Uso terapeutico di nuove preparazioni farmaceutiche contenenti farmaci antitumorali legati all'acido ialuronico nel trattamento delle neoplasie
KR20110032561A (ko) * 2009-09-23 2011-03-30 포항공과대학교 산학협력단 약물 전달체의 표적 특이성 조절 방법, 표적 특이적 약물 전달체, 및 표적-비특이적 약효 장기 지속성 약물 전달체
CN102399295B (zh) 2010-09-09 2013-11-06 常州百瑞吉生物医药有限公司 低巯基化改性度生物相容高分子巯基化衍生物及其交联材料和用途
EP2988755A4 (en) * 2013-04-25 2016-11-30 Aluron Biopharma Inc RETICULATED HYALURONIC ACID COMPOSITIONS
WO2015005459A1 (ja) * 2013-07-10 2015-01-15 生化学工業株式会社 呼吸器投与用の医薬組成物
CZ2014150A3 (cs) * 2014-03-11 2015-05-20 Contipro Biotech S.R.O. Konjugáty oligomeru kyseliny hyaluronové nebo její soli, způsob jejich přípravy a použití
CN104497167B (zh) * 2014-11-24 2017-05-17 山东省药学科学院 透明质酸衍生物及其治疗药物
CN105727305B (zh) * 2016-02-24 2018-09-07 温州医科大学 一种Legumain响应释放阿霉素缓释纳米制剂及制备方法与作为制备载体药物的应用
CN112334167A (zh) 2018-06-15 2021-02-05 克罗马药品有限责任公司 包含交联聚合物的水凝胶组合物
BR112020024654B1 (pt) 2018-06-15 2024-02-27 Croma-Pharma Gmbh Composição de hidrogel estéril, unidade de aplicação para injeção,seus usos, método cosmético, enchimento de tecido mole, e implante ou depósito
CN108912245B (zh) * 2018-07-13 2020-04-28 吉林大学 一种具有靶向性和抗炎活性的氟化透明质酸衍生物及其制备方法和应用
WO2020067507A1 (ja) * 2018-09-28 2020-04-02 生化学工業株式会社 第１級アミン化合物又は第２級アミン化合物－酸性多糖コンジュゲートとその製造方法
WO2021123247A1 (en) 2019-12-19 2021-06-24 Croma-Pharma Gmbh Thiol-modified hyaluronan and hydrogel comprising the crosslinked hyaluronan
US11643431B2 (en) * 2020-06-08 2023-05-09 Aihol Corporation Uses of hyaluronan conjugate
CN111892668B (zh) * 2020-07-03 2022-07-12 广东工业大学 一种化合物及其制备方法、荧光探针和抗肿瘤药物
CN112089690A (zh) * 2020-08-31 2020-12-18 厦门大学 一种透明质酸化青蒿琥酯、其纳米胶束制剂及其制备方法和用途
CN112608397B (zh) * 2020-11-30 2021-12-28 西安交通大学 一种铂类抗肿瘤药物-多糖聚合物纳米前药及制备方法和应用
CN116782906A (zh) * 2021-06-18 2023-09-19 爱禾公司 透明质酸复合物的用途
WO2025174913A1 (en) * 2024-02-12 2025-08-21 Prolynx Llc Locoregional therapies using slow-release conjugates

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH666897A5 (fr) 1983-10-11 1988-08-31 Fidia Spa Fractions d'acide hyaluronique non inflammatoire, procedes et compositions pharmaceutiques.
US4851521A (en) 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
IT1219587B (it) 1988-05-13 1990-05-18 Fidia Farmaceutici Polisaccaridi carbossiilici autoreticolati
EP0506976B1 (en) * 1990-10-18 1997-04-09 Shiseido Company Limited Combination of hyaluronic acid with medicinal ingredient and production thereof
IT1247175B (it) 1991-04-19 1994-12-12 Fidia Spa Procedimento per la purificazione di acido ialuronico e frazione di acido ialuronico puro per uso oftalmico.
AU4406793A (en) 1992-06-04 1993-12-30 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
JP2610792B2 (ja) 1993-02-26 1997-05-14 株式会社ディ・ディ・エス研究所 多糖誘導体および薬物担体
GB9320781D0 (en) * 1993-10-08 1993-12-01 Erba Carlo Spa Polymer-bound camptothecin derivatives
US5616568A (en) * 1993-11-30 1997-04-01 The Research Foundation Of State University Of New York Functionalized derivatives of hyaluronic acid
ITPD940054A1 (it) 1994-03-23 1995-09-23 Fidia Advanced Biopolymers Srl Polisaccaridi solfatati
CA2192725C (en) 1995-12-28 2004-04-20 Kenji Tsujihara Camptothecin derivatives
PL189698B1 (pl) 1996-03-12 2005-09-30 Pg Txl Co Kompozycja farmaceutyczna zawierająca lek przeciwnowotworowy i jej zastosowania
TW409058B (en) 1996-06-06 2000-10-21 Daiichi Seiyaku Co Method for preparation of a drug complex
ITPD980169A1 (it) 1998-07-06 2000-01-06 Fidia Advanced Biopolymers Srl Ammidi dell'acido ialuronico e dei suoi derivati e processo per la loro preparazione.
KR20020082888A (ko) * 2000-03-17 2002-10-31 쎌세러퓨틱스,인코포레이티드 폴리글루탐산-캄프토테신 컨주게이트 및 제조 방법
GB0012718D0 (en) * 2000-05-24 2000-07-19 Angeletti P Ist Richerche Bio Conjugates of aminodrugs
IT1317358B1 (it) 2000-08-31 2003-06-16 Fidia Advanced Biopolymers Srl Derivati cross-linkati dell'acido ialuronico.
IT1317359B1 (it) 2000-08-31 2003-06-16 Fidia Advanced Biopolymers Srl Polisaccaridi percarbossilati, quali l'acido ialuronico, processo perla loro preparazione e loro impiego in campo farmaceutico e
CA2444483A1 (en) * 2001-04-26 2002-11-07 Board Of Regents, The University Of Texas System Diagnostic imaging compositions, their methods of synthesis and use
CA2445985A1 (en) * 2001-05-04 2002-11-14 University Of Utah Research Foundation Hyaluronic acid containing bioconjugates: targeted delivery of anti-cancer drugs to cancer cells
US7034127B2 (en) * 2002-07-02 2006-04-25 Genzyme Corporation Hydrophilic biopolymer-drug conjugates, their preparation and use
ITPD20020271A1 (it) 2002-10-18 2004-04-19 Fidia Farmaceutici Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati.

Also Published As

Publication number Publication date
KR101614157B1 (ko) 2016-04-20
EP2548582B1 (en) 2018-09-19
AU2006274992A1 (en) 2007-02-08
CN103041402A (zh) 2013-04-17
PL2537533T3 (pl) 2017-10-31
JP2014001249A (ja) 2014-01-09
JP2009503010A (ja) 2009-01-29
SI1909843T1 (sl) 2017-01-31
ES2596877T3 (es) 2017-01-12
ES2692619T3 (es) 2018-12-04
IL189078A0 (en) 2008-08-07
EP2540319A1 (en) 2013-01-02
AU2006274992B2 (en) 2012-03-08
WO2007014784A2 (en) 2007-02-08
DK2540319T3 (en) 2017-08-21
CN101267840B (zh) 2015-07-08
ITPD20050242A1 (it) 2007-02-04
RU2411958C2 (ru) 2011-02-20
KR20080032235A (ko) 2008-04-14
NO20080564L (no) 2008-05-05
ES2633291T3 (es) 2017-09-20
DK2537533T3 (da) 2017-08-21
NZ565504A (en) 2011-02-25
WO2007014784A3 (en) 2007-05-18
EP1909843A2 (en) 2008-04-16
SI2540319T1 (sl) 2017-08-31
CA2616957A1 (en) 2007-02-08
PL2540319T3 (pl) 2017-10-31
JP5457672B2 (ja) 2014-04-02
BRPI0614536A2 (pt) 2012-11-27
RU2008102878A (ru) 2009-09-10
EP2537533B1 (en) 2017-05-17
HK1118011A1 (zh) 2009-01-30
EP2548582A1 (en) 2013-01-23
WO2007014784A9 (en) 2007-07-12
EP2540319B1 (en) 2017-05-10
CA2616957C (en) 2016-04-26
SI2537533T1 (sl) 2017-10-30
EP2537533A3 (en) 2013-01-09
US20080292703A1 (en) 2008-11-27
EP1909843B1 (en) 2016-09-21
CN101267840A (zh) 2008-09-17
US9687558B2 (en) 2017-06-27
ES2633290T3 (es) 2017-09-20
EP2537533A2 (en) 2012-12-26

Similar Documents

Publication Publication Date Title
NO20200320A1 (no) Sammensetninger og fremgangsmåter for fremstilling av lite vannoppløselige medikamenter med økt stabilitet
IL199151A (en) Pyrimidine derivatives, their pharmaceutical preparations, their use in cancer treatment and their kits
GB2431876B (en) Use of para-coumaric acid or para-hydroxycinnamic acid derivatives in cosmetic or dermatological compositions
PL1861387T3 (pl) Pochodne benzoimidazolu i ich kompozycje farmaceutyczne
IL197451A (en) History of Phenylamino and 4-Phenylalkylamino Quinazoline and Pharmaceuticals Containing It
IL193467A0 (en) Substituted indazole derivatives, their manufacture and use as pharmaceutical agents
BRPI0813105A2 (pt) Derivado de sulfonamida de ácido malônico e uso faramacêutico do mesmo
BRPI0720124A2 (pt) Composições farmacêuticas e seus métodos de uso.
SI1909843T1 (sl) Protitumorski biokonjugati hialuronske kisline ali njenih derivatov, dobljeni z indirektno kemijsko konjugacijo, in njihova uporaba na farmacevtskem področju
IL184735A0 (en) Pharmaceutical formulations and methods of use
CR10229A (es) Derivados de 1,2,4,5,-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
SMT201300080B (it) Derivati di carbammati di alchiltiazoli, loro preparazione e loro utilizzo come inibitori dell'enzima faah
DK1922309T3 (da) N-phenyl-2-pyrimidin-aminderivater og fremgangsmåde til fremstillingen deraf
PT1861387E (pt) Derivados de benzimidazol e composições farmacêuticas dos mesmos
IL194880A (en) Aminazole amine derivatives, their use in the treatment of diseases and pharmaceuticals containing them
BRPI0910570A2 (pt) uso de bioconjugados, e, formulações farmacêuticas
BRPI0821455A2 (pt) Composições farmacêuticas de amlopidina e valsartan
ITPD20050168A1 (it) Formulazioni di acido lipoico ed acido ialuronico e o suoi derivati e loro impiego in campo farmaceutico e cosmetico
DK2222275T3 (da) Farmaceutiske sammensætninger indeholdende bradykininantagonister og hyaluronsyre og anvendelser deraf
PT1858481T (pt) Composições oftalmológicas e sua utilização
ZA200804163B (en) New adjuvants on the basis of bisacyloxypropylcysteine conjugates and derivatives and their uses in pharmaceutical compositions
PL377180A1 (pl) Zastosowanie izoflawonów i ich pochodnych w leczeniu mukopolisacharydoz
IL185096A0 (en) Polymer compositions and their use in the production of active or effective ingredient compositions
IL186745A0 (en) New thiazolidinones without basic nitrogen, their production and use as pharmaceutical agents
BRPI0719997A2 (pt) Uso de epotilonas no tratamento de osteoporose e doenças relacionadas